Richard A Monaghan

US Patent:

7294646, Nov 13, 2007

Filed:

Jun 13, 2003

Appl. No.:

10/511731

Inventors:

Maria L. Garcia - Edison NJ, US
Michael A. Goetz - Scotch Plains NJ, US
Gregory J. Kaczorowski - Edison NJ, US
Owen B. McManus - Skillman NJ, US
Richard L. Monaghan - Morristown NJ, US
William R. Strohl - Bridgewater NJ, US
Jan S. Tkacz - Piscataway NJ, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A61K 31/40
C07D 487/00

US Classification:

514410, 548417

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.

US Patent:

20050239787, Oct 27, 2005

Filed:

Jun 13, 2003

Appl. No.:

10/511664

Inventors:

Michael Goetz - Scotch Plains NJ, US
Gregory Kaczorowski - Edison NJ, US
Richard Monaghan - Morristown NJ, US
William Strohl - Bridgewater NJ, US
Jan Tkacz - Piscataway NJ, US

International Classification:

A61K031/498
A61K031/407
A61K031/404

US Classification:

514249000, 514410000, 514414000, 514415000

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.

US Patent:

44761392, Oct 9, 1984

Filed:

Sep 29, 1982

Appl. No.:

6/426585

Inventors:

August J. Kempf - Staten Island NY
Kenneth E. Wilson - Westfield NJ
Otto D. Hensens - Middletown NJ
Richard L. Monaghan - Somerset NJ
Sheldon B. Zimmerman - Springfield NJ
Eugene L. Dulaney - Summit NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3135
C07D30904

US Classification:

424283

Abstract:

The antibiotic, L-681,217, having antibacterial and growth-permittant activity, is produced by fermentation of Streptomyces cattleya in a suitable nutrient media.

US Patent:

43306241, May 18, 1982

Filed:

Dec 3, 1980

Appl. No.:

6/212385

Inventors:

Enrique Tejera - Caracas, VE
Sara A. Currie - Roselle NJ
James E. Flor - Bridgewater NJ
Richard L. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 1960

US Classification:

435 75

Abstract:

The antibiotic Tunicamycin is produced by fermenting a Tunicamycin-producing strain of Streptomyces (Streptomyces griseus ATCC 31591) under controlled conditions in a suitable nutrient medium and isolating the antibiotic so produced from the fermentation medium.

US Patent:

49686089, Nov 6, 1990

Filed:

Oct 7, 1987

Appl. No.:

7/105797

Inventors:

Robert A. Giacobbe - Lavallette NJ
Sagrario M. Del Val - Madrid, ES
Richard L. Monaghan - Somerset NJ
Robert E. Schwartz - Westfield NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 102
C12N 100
C12N 138
C12N 114

US Classification:

435 71

Abstract:

An antifungal agent produced by cultivation of Zalerion arboricola is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity. Its production and isolation are also described.

US Patent:

55785816, Nov 26, 1996

Filed:

Apr 26, 1994

Appl. No.:

8/233489

Inventors:

Prakash S. Masurekar - Warren NJ
Wesley L. Shoop - Somerville NJ
Michael A. Wallace - Lebanon NJ
Richard L. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3170
C07H 1708

US Classification:

514 30

Abstract:

An active avermectin analogue which can be produced by directed biosynthesis is described. The compound, named 26-R-Avermectin B. sub. 1 a, is active in the Haemonchus egg to L3 assay and has the following structure: ##STR1##.

US Patent:

53188950, Jun 7, 1994

Filed:

Oct 5, 1992

Appl. No.:

7/956716

Inventors:

Jennifer N. Kahn - East Brunswick NJ
Kevin M. Byrne - West Trenton NJ
Louis Kaplan - New City NY
Richard J. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 118
C12N 100
C07D49800

US Classification:

435 32

Abstract:

Disclosed are new Aspergillus niger mutants which can be used for identifying active FK-506/ rapamycin type, or cyclosporin A type inununosuppressants in a broth, natural product extract, or composition exhibiting inununosuppressant activity. Specifically disclosed are the new mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A.

US Patent:

53170318, May 31, 1994

Filed:

Nov 24, 1992

Appl. No.:

7/982163

Inventors:

John G. MacConnell - Watchung NJ
Byron H. Arison - Watchung NJ
George A. Doss - Westfield NJ
Richard L. Monaghan - Somerset NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31335

US Classification:

514452

Abstract:

Cholesterol lowering compounds and compositions are formed from the photochemical treatment of the Zaragozic Acids followed by esterification. These compounds and compositions are active squalene synthetase inhibitors useful in the treatment of hypercholesterolemia.